KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to -$501.4 million.

  • Eli Lilly's Deferred Taxes fell 21665.89% to -$501.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 1336.27%. This contributed to the annual value of $2.7 billion for FY2024, which is 1461.34% up from last year.
  • Eli Lilly's Deferred Taxes amounted to -$501.4 million in Q3 2025, which was down 21665.89% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Eli Lilly's Deferred Taxes peaked at $1.1 billion during Q3 2022, and registered a low of -$501.4 million during Q3 2025.
  • For the 5-year period, Eli Lilly's Deferred Taxes averaged around $472.1 million, with its median value being $431.1 million (2023).
  • As far as peak fluctuations go, Eli Lilly's Deferred Taxes soared by 496730.77% in 2023, and later plummeted by 21665.89% in 2025.
  • Quarter analysis of 5 years shows Eli Lilly's Deferred Taxes stood at $92.5 million in 2021, then tumbled by 111.24% to -$10.4 million in 2022, then surged by 4967.31% to $506.2 million in 2023, then skyrocketed by 90.97% to $966.7 million in 2024, then tumbled by 151.87% to -$501.4 million in 2025.
  • Its Deferred Taxes was -$501.4 million in Q3 2025, compared to $1.1 billion in Q2 2025 and $391.6 million in Q1 2025.